Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA 98101.
Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA 98101;
Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):5931-5937. doi: 10.1073/pnas.1918167117. Epub 2020 Mar 3.
E-cadherin is a tumor suppressor protein, and the loss of its expression in association with the epithelial mesenchymal transition (EMT) occurs frequently during tumor metastasis. However, many metastases continue to express E-cadherin, and a full EMT is not always necessary for metastasis; also, positive roles for E-cadherin expression in metastasis have been reported. We hypothesize instead that changes in the functional activity of E-cadherin expressed on tumor cells in response to environmental factors is an important determinant of the ability of the tumor cells to metastasize. We find that E-cadherin expression persists in metastatic lung nodules and circulating tumor cells (CTCs) in two mouse models of mammary cancer: genetically modified MMTV-PyMT mice and orthotopically grafted 4T1 tumor cells. Importantly, monoclonal antibodies that bind to and activate E-cadherin at the cell surface reduce lung metastasis from endogenous genetically driven tumors and from tumor cell grafts. E-cadherin activation inhibits metastasis at multiple stages, including the accumulation of CTCs from the primary tumor and the extravasation of tumor cells from the vasculature. These activating mAbs increase cell adhesion and reduce cell invasion and migration in both cell culture and three-dimensional spheroids grown from primary tumors. Moreover, activating mAbs increased the frequency of apoptotic cells without affecting proliferation. Although the growth of the primary tumors was unaffected by activating mAbs, CTCs and tumor cells in metastatic nodules exhibited increased apoptosis. Thus, the functional state of E-cadherin is an important determinant of metastatic potential beyond whether the gene is expressed.
E-钙黏蛋白是一种肿瘤抑制蛋白,其表达的丧失与上皮间质转化(EMT)有关,在肿瘤转移过程中经常发生。然而,许多转移仍然表达 E-钙黏蛋白,并且转移并不总是需要完全的 EMT;此外,E-钙黏蛋白表达在转移中的积极作用也有报道。我们假设,肿瘤细胞表达的 E-钙黏蛋白的功能活性的变化,是肿瘤细胞转移能力的一个重要决定因素,而不是其表达的丧失。我们发现,在两种乳腺癌小鼠模型中,即遗传修饰的 MMTV-PyMT 小鼠和原位移植的 4T1 肿瘤细胞中,转移性肺结节和循环肿瘤细胞(CTC)中仍然存在 E-钙黏蛋白的表达。重要的是,与细胞表面的 E-钙黏蛋白结合并激活其的单克隆抗体可减少源自内源性遗传驱动肿瘤和肿瘤细胞移植的肺转移。E-钙黏蛋白的激活抑制了多个阶段的转移,包括从原发性肿瘤中积累 CTC 以及肿瘤细胞从血管中渗出。这些激活的单克隆抗体在细胞培养和从原发性肿瘤生长的三维球体中均增加了细胞黏附,并减少了细胞侵袭和迁移。此外,激活的单克隆抗体增加了凋亡细胞的频率,而不影响增殖。尽管激活的单克隆抗体对原发性肿瘤的生长没有影响,但转移性结节中的 CTC 和肿瘤细胞凋亡增加。因此,E-钙黏蛋白的功能状态是转移潜力的一个重要决定因素,而不仅仅是基因的表达。